S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself

Idorsia Stock Price, News & Analysis (OTCMKTS:IDRSF)

$2.10
0.00 (0.00%)
(As of 11/29/2023 ET)
Compare
Today's Range
$2.10
$2.10
50-Day Range
$1.65
$4.10
52-Week Range
$1.65
$19.14
Volume
N/A
Average Volume
6,625 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IDRSF stock logo

About Idorsia Stock (OTCMKTS:IDRSF)

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

IDRSF Stock Price History

IDRSF Stock News Headlines

Idorsia (OTCMKTS:IDRSF) Trading Down 14.3%
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Idorsia Shares Fall on Funding Needs
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Idorsia reacquires the world-wide rights to aprocitentan
Idorsia Ltd (IDIA.SW)
Are Investors Undervaluing Idorsia Ltd (VTX:IDIA) By 38%?
Idorsia: Restructuring In Place
Idorsia announces a change to commercial leadership
See More Headlines
Receive IDRSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IDRSF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jean-Paul Clozel M.D. (Age 68)
    CEO & Executive Director
    Comp: $1.53M
  • Mr. André C. Muller (Age 60)
    Executive VP & CFO
  • Dr. Martine Clozel (Age 68)
    Executive VP & Chief Scientific Officer
  • Mr. Andrew C. Weiss (Age 55)
    Senior VP and Head of Investor Relations & Corporate Communications
  • Mr. Julien Gander L.L.M. (Age 44)
    Senior VP, Group General Counsel & Company Secretary
  • Mr. Alexander Khatuntsev (Age 45)
    Senior VP & Head of Global Human Resources
  • Dr. Guy Braunstein M.D. (Age 67)
    Executive VP & Chief Medical Officer
  • Mr. Olivier Lambert (Age 57)
    Senior VP & Head of Technical Operations
  • Mr. Markus A. Riederer (Age 61)
    Senior VP & Head of Drug Discovery Biology
  • Mr. Christoph Boss (Age 55)
    Senior VP & Head of Drug Discovery Chemistry














IDRSF Stock Analysis - Frequently Asked Questions

Should I buy or sell Idorsia stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 4 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "strong sell" IDRSF shares.
View IDRSF analyst ratings
or view top-rated stocks.

How have IDRSF shares performed in 2023?

Idorsia's stock was trading at $14.69 at the beginning of 2023. Since then, IDRSF stock has decreased by 85.7% and is now trading at $2.10.
View the best growth stocks for 2023 here
.

How do I buy shares of Idorsia?

Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:IDRSF) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -